Business
Bolt Biotherapeutics to Present Preclinical Data for BDC-3042, a Dectin-2-Targeting Agonistic Antibody, at 2023 AACR Annual Meeting
REDWOOD CITY, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel
About this update from Bolt Biotherapeutics, Inc.
[{"type":"text","content":"REDWOOD CITY, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immuno-oncology therapeutics for the treatment of cancer, today announced that it will present a poster with new preclinical data for BDC-3042, a Dectin-2-targeting agonistic antibody, at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2023. The conference is being held at the Orange County Convention Center in Orlando, Fla. from April 14-19, 2023. “We are excited about BDC-3042 and its novel mechanism of action targeting tumor-associated macrophages. BDC-3042 has the potential to treat many types of cancer,” said Randall Schatzman, Ph.D., Chief Executive Officer of Bolt Biotherapeutics. “We will be presenting new data in our AACR poster demonstrating recent progress in the development of this proprietary program. We look forward to advancing BDC-3042 into the clinic this year.” Details about the presentation can be found below and on the AACR website. Additionally, a copy of the poster will be available on the Publications page of the Bolt Biotherapeutics website following the conference. Title: Targeting tumor-associated macrophages to enhance anti-tumor immunity with the Dectin-2 agonistic antibody BDC-3042Poster Board Number: 11 Abstract Presentation Number: 2964 Presenter: Justin A. Kenkel, Ph.D.Details: Monday, April 17, 2023, 1:30 p.m. – 5:00 p.m. EDTLocation: Orange County Convention Center, Section 24 Key Findings from the Study Tumor-associated macrophages (TAMs) are an abundant immune cell population in many solid tumors and play a key role in establishing the immunosuppressive tumor microenvironment that enables tumor progression. However, TAMs have the potential to be reprogrammed into immunostimulatory cells that enhance innate and adaptive anti-tumor immunity. BDC-3042 is an agonistic antibody targeting Dectin-2, an immune-activating receptor expressed by TAMs. Given that Dectin-2 is over-expressed in many human cancers, BDC-3042 has broad applicability as an anti-cancer therapy. BDC-3042 exhibits strong binding to Dectin-2-expressing primary human TAMs from a range of solid tumor types.BDC-3042 activates primary human TAMs to produce an array of pro-inflammatory cytokines and chemokines associated with anti-tumor immunity.BDC-3042 elic...